Respules Global Market Report 2024

The respules market size has grown strongly in recent years. It will grow from $1.69 billion in 2023 to $1.83 billion in 2024 at a compound annual growth rate (CAGR) of 7.9%. The growth observed in the historical period can be ascribed to factors such as recommendations from physicians, enhancements in healthcare access, advancements in clinical research and development, increased adoption of inhalation therapy, awareness campaigns, and growth in the pharmaceutical industry.

The respules market size is expected to see strong growth in the next few years. It will grow to $2.48 billion in 2028 at a compound annual growth rate (CAGR) of 7.9%. The anticipated growth in the forecast period can be credited to progress in drug formulations, the advent of biologic therapies, the integration of smart inhalers and connectivity, the adoption of personalized medicine approaches, the rise of telemedicine and remote care, and regulatory backing for inhalation therapy. Noteworthy trends expected in the forecast period encompass sustainable manufacturing practices, the development of remote monitoring and compliance tools, the emergence of patient-centric inhalation solutions, the advancement of respiratory inhalation vaccines, and the introduction of customizable dosage respules.

The growth in the respules market is anticipated to be propelled by the increasing incidence of respiratory disorders. Respiratory disorders encompass various lung diseases such as tuberculosis, lung cancer, pulmonary hypertension, mesothelioma, cystic fibrosis, emphysema, and asthma. Respules serve as a treatment for a range of respiratory disorders, addressing conditions such as bronchial asthma, emphysema, spasmodic stenosis, and abnormal bronchial mucus production. As an illustration, data from the Australian Institute of Health and Welfare in June 2023 revealed that in 2021, there were approximately 6,551 deaths related to chronic respiratory conditions in Australia, accounting for 27.1% of all deaths. Moreover, chronic obstructive pulmonary disease (COPD) constituted 2.6% of underlying-cause respiratory deaths. Hence, the escalating incidence of respiratory disorders is a key driver for the respules market.

The surge in air pollution is also expected to contribute to the growth of the respules market. Air pollution, characterized by the presence of harmful substances and contaminants in the Earth's atmosphere, poses risks to human health, the environment, and the climate. Respules often contain bronchodilators or corticosteroids to alleviate symptoms such as wheezing and shortness of breath, which can be triggered by exposure to air pollution. For example, data from IQAir in September 2021 highlighted a 25% increase in PM2.5 concentrations in Malaysia compared to the previous year, and 11 out of the 15 most polluted cities in Central and South Asia were located in India. Delhi, specifically, experienced a 14.6% surge in PM2.5 concentrations, surpassing WHO air quality guidelines. The rise in air pollution levels is thus contributing to the growth of the respules market.

Major players in the respules market are introducing novel products, such as inhalation suspensions, to secure a competitive advantage. Inhalation suspensions are pharmaceutical formulations characterized by finely dispersed solid or liquid particles suspended in a liquid medium. A notable example is The Ritedose Corporation, a US-based pharmaceutical company, which unveiled a new single unit dose generic product for hospitals in December 2021, Budesonide Inhalation Suspension (0.5 mg/2 ml). This product, featuring 30 single-dose ampules per carton, individually wrapped and barcoded, provides hospitals with a dependable and substantial supply. Budesonide inhalation suspension typically incorporates the corticosteroid budesonide, serving as an anti-inflammatory agent for managing respiratory conditions by mitigating inflammation and associated symptoms in diseases such as asthma.

Leading companies in the respules market are also engaging in strategic partnerships to fortify their market positions and introduce innovative products. Collaborations and partnerships in this market facilitate broader market reach, expanded distribution networks, and heightened research and development initiatives, thereby contributing to the success and growth of respiratory medication products. For instance, in July 2023, Viatris Inc., a US-based pharmaceutical company, collaborated with Kindeva Drug Delivery L.P., a US-based pharmaceutical contract development and manufacturing organization (CDMO), to jointly launch Breyna (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol. As the first FDA-approved generic version of AstraZeneca's Symbicort for asthma and chronic obstructive pulmonary disease (COPD), Breyna offers accessible and cost-effective treatment options for individuals facing respiratory challenges. Available in 80 mcg/4.5 mcg and 160 mcg/4.5 mcg dosage strengths, Breyna addresses the maintenance treatment of airflow obstruction, reduces exacerbations in COPD patients, and manages asthma symptoms in patients six years and older.

In February 2022, Glenmark Pharmaceuticals, an India-based pharmaceutical company, collaborated with AstraZeneca, a UK-based pharmaceutical and biotechnology company, to commercialize Pulmicort Respules in Colombia. As part of this agreement, AstraZeneca retains the production and registration ownership of Pulmicort Respules, ensuring continued and expanded access to this essential treatment for people living with asthma in Colombia.

Major companies operating in the respules market report are AstraZeneca PLC, GlaxoSmithKline PLC, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sandoz International GmbH, Macleods Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Cipla Limited, Intas Pharmaceuticals Ltd., Lupin Limited, Cadila Healthcare Limited, Torrent Pharmaceuticals Ltd., Glenmark Pharmaceuticals Ltd., Jubilant Life Sciences Limited, Ranbaxy Laboratories Limited, Systopic Laboratories Pvt. Ltd., Ultratech India Limited, Koye Pharmaceuticals Pvt. Ltd., Amanta Healthcare Ltd., Lucky Pharmaceuticals, Medicamen Biotech Limited, Axa Parenterals Ltd., Zuche Pharmaceuticals Pvt. Ltd., Jaksh Pharma, Biochemix Healthcare Private Limited, Intra Life Pvt. Ltd., Wellona Pharmaceuticals Private Limited, Percept Pharma Limited, Eurocrit Labs, Iskon Remedies.

North America was the largest region in the respules market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the respules market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the respules market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The primary categories of respule drugs include budesonide, albuterol, ipratropium bromide, salbutamol sulfate, and ipratropium bromide. Budesonide is a synthetically produced glucocorticoid steroid known for its potent topical anti-inflammatory properties. Various dosage types and strengths, such as 0.25 mg/2 ml, 0.5 mg/2 ml, 1 mg/2 ml, and others, are available and distributed through various channels, including hospital pharmacies, retail pharmacies, online pharmacies, and more.

The respules market research report is one of a series of new reports that provides respules market statistics, including respules industry global market size, regional shares, competitors with a respules market share, detailed respules market segments, market trends and opportunities, and any further data you may need to thrive in the respules industry. This respules market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The respule market consists of sales of budesonide, disodium edetate, sodium chloride, citric acid, and sterile solution. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).


The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.